Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

E-resources

PDF

Peer reviewed Open access

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Bakris, George L; Agarwal, Rajiv; Anker, Stefan D; Pitt, Bertram; Ruilope, Luis M; Rossing, Peter; Kolkhof, Peter; Nowack, Christina; Schloemer, Patrick; Joseph, Amer; Filippatos, Gerasimos

The New England journal of medicine, 12/2020, Volume: 383, Issue: 23

Journal Article

In this double-blind trial, patients with chronic kidney disease and type 2 diabetes were randomly assigned to receive the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone or placebo. Treatment with finerenone resulted in lower risks of chronic kidney disease outcomes and cardiovascular outcomes than placebo.

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme